Total trials
138
Active
20
Phase 3
7
Total enrollment
24,064
Pipeline matrix
Showing 19 of 19 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ketamine | — | — | — | — | — | 3 | |
| Interscalene block with the addition of buprenorphine, clonidine, dexamethasone | — | — | — | — | — | 1 | |
| Interscalene block with buprenorphine alone | — | — | — | — | — | 1 | |
| IPACK | — | — | — | — | — | 1 | |
| Insulin glargine | — | — | — | — | — | 1 | |
| insulin NPH | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 3 | |
| Shingrix | — | — | — | — | — | 1 | |
| Decitabine | — | — | — | — | — | 1 | |
| Paclitaxel | — | — | — | — | — | 1 | |
| Selinexor | — | — | — | — | — | 1 | |
| cyclophosphamide | — | — | — | — | 4 | ||
| Dose 1 | — | — | — | — | — | 1 | |
| Dose 2 | — | — | — | — | — | 1 | |
| Dose 3 | — | — | — | — | — | 1 | |
| Dose 4 | — | — | — | — | — | 1 | |
| Fludarabine | — | — | — | — | — | 1 | |
| CD19-CD34 CAR transduced T cells | — | — | — | — | — | 1 | |
| Escalating Doses | — | — | — | — | — | 1 |
Next readouts
- 2022-08-11
- 2025-03-07
- 2025-08-03
- 2026-04-01
- 2026-06-30
- 2028-05-31
- 2028-09
- 2028-09
- 2030-08-28
Top conditions
- Obesity7
- Diabetes6
- Ovarian Cancer5
- Overactive Bladder5
- Pelvic Organ Prolapse4
- Pain4
- Stress Urinary Incontinence3
- Depression3
Frequently asked questions about Loyola University
- How many clinical trials does Loyola University have on ClinicalTrials.gov?
- Loyola University is listed as the lead sponsor on 138 clinical trials in ClinicalTrials.gov, 20 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Loyola University's trials are in Phase 3?
- 7 of Loyola University's trials are in Phase 3, spread across 19 active drug programs.
- What therapeutic areas does Loyola University focus on?
- Loyola University's most-studied conditions on ClinicalTrials.gov are Obesity, Diabetes, Ovarian Cancer, Overactive Bladder, Pelvic Organ Prolapse.
- When are Loyola University's next clinical trial readouts?
- Loyola University has 9 upcoming primary-completion readouts tracked here; the soonest is “CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies”, expected around 2022-08-11.